On every alternate day, a new anticancer medicine is announced to ease the life of cancer patient from the view of the quality and quantity of Life. Few are very costly unaffordable to many, most are claimed that they are less toxic and better effective for patient survival and a better life. But the majority of new oncology drugs that were approved by the European Medicines Agency (EMA) from 2009 to 2013 entered the market without clear evidence that they improved survival or quality of life, according to a new report in the BMJ.
During this period, the EMA approved the use of 48 cancer drugs for 68 indications. Of these 68 indications, 39 (57%) approvals were made on the basis of a surrogate endpoint in the absence of evidence of a survival benefit or an improvement in the quality of life. At a median of follow-up of 5.4 years in the postmarketing period, only 35 (51%) drugs showed a…
